NICE will be flexible - up to a point
This article was originally published in Scrip
Executive Summary
NICEis never far from controversy, and its interim decision to reject the use of four novel kidney drugs in the national health serviceis no exception. It shows that the institute is still prepared to base its recommendations firmly on cost-benefit assessments.